CDKL5 is a brain MeCP2 target gene regulated by DNA methylation

Neurobiology of Disease

Volumn 38, Issue 3, 2010, Pages 414-424

  Carouge, Delphine ^a   Host, Lionel ^a   Aunis, Dominique ^a   Zwiller, Jean ^a,b   Anglard, Patrick ^a,b  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b Université de Strasbourg Faculté de Psychologie   (France)

Author keywords

Chromatin remodeling; DNA methylation; Drug of abuse; Epigenetics; MeCP2; Neurodevelopmental disorders; Rett syndrome

Indexed keywords

COCAINE; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE LIKE 5; DNA METHYLTRANSFERASE INHIBITOR; GENOMIC DNA; METHYL CPG BINDING PROTEIN 2; SEROTONIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL TISSUE; ARTICLE; CELL LINE; CELL STRAIN; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CORPUS STRIATUM; DNA METHYLATION; DNA SEQUENCE; GENE CONTROL; GENE MUTATION; GENE REPRESSION; IMMUNOHISTOCHEMISTRY; MALE; NERVE CELL PLASTICITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMID; PRIORITY JOURNAL; PROTEIN BINDING; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; BRAIN; COCAINE; CORPUS STRIATUM; DNA METHYLATION; DNA-CYTOSINE METHYLASES; DOPAMINE UPTAKE INHIBITORS; GENE KNOCKDOWN TECHNIQUES; MALE; METHYL-CPG-BINDING PROTEIN 2; PC12 CELLS; PROTEIN-SERINE-THREONINE KINASES; RATS; RATS, WISTAR; RNA, SMALL INTERFERING; SEQUENCE ANALYSIS, DNA; SEROTONIN;

EID: 77952553247     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2010.02.014     Document Type: Article

References (63)

1. Amir R.E., Van den Veyver I.B., Wan M., Tran C.Q., Francke U., Zoghbi H.Y. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat. Genet. 1999, 23:185-188.
2. Artuso R., Mencarelli M.A., Polli R., Sartori S., Ariani F., Pollazzon M., Marozza A., Cilio M.R., Specchio N., Vigevano F., Vecchi M., Boniver C., Bernardina B.D., Parmeggiani A., Buoni S., Hayek G., Mari F., Renieri A., Murgia A. Early-onset seizure variant of Rett syndrome: definition of the clinical diagnostic criteria. Brain Dev. 2009, 32:17-24.
3. Bahi-Buisson N., Nectoux J., Rosas-Vargas H., Milh M., Boddaert N., Girard B., Cances C., Ville D., Afenjar A., Rio M., Heron D., N'Guyen Morel M.A., Arzimanoglou A., Philippe C., Jonveaux P., Chelly J., Bienvenu T. Key clinical features to identify girls with CDKL5 mutations. Brain 2008, 131:2647-2661.
4. Bertani I., Rusconi L., Bolognese F., Forlani G., Conca B., De Monte L., Badaracco G., Landsberger N., Kilstrup-Nielsen C. Functional consequences of mutations in CDKL5, an X-linked gene involved in infantile spasms and mental retardation. J. Biol. Chem. 2006, 281:32048-32056.
5. Bird A. Molecular biology. Methylation talk between histones and DNA. Science 2001, 294:2113-2115.
6. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev. 2002, 16:6-21.
7. Brena R.M., Huang T.H., Plass C. Toward a human epigenome. Nat. Genet. 2006, 38:1359-1360.
8. Cameron E.E., Bachman K.E., Myohanen S., Herman J.G., Baylin S.B. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. 1999, 21:103-107.
9. Cassel S., Revel M.O., Kelche C., Zwiller J. Expression of the methyl-CpG-binding protein MeCP2 in rat brain. An ontogenetic study. Neurobiol. Dis. 2004, 15:206-211.
10. Cassel S., Carouge D., Gensburger C., Anglard P., Burgun C., Dietrich J.B., Aunis D., Zwiller J. Fluoxetine and cocaine induce the epigenetic factors MeCP2 and MBD1 in adult rat brain. Mol. Pharmacol. 2006, 70:487-492.
11. Chahrour M., Zoghbi H.Y. The story of Rett syndrome: from clinic to neurobiology. Neuron 2007, 56:422-437.
12. Champagne F.A., Curley J.P. Epigenetic mechanisms mediating the long-term effects of maternal care on development. Neurosci. Biobehav. Rev. 2009, 33:593-600.
13. Champagne F.A., Weaver I.C., Diorio J., Dymov S., Szyf M., Meaney M.J. Maternal care associated with methylation of the estrogen receptor-alpha1b promoter and estrogen receptor-alpha expression in the medial preoptic area of female offspring. Endocrinology 2006, 147:2909-2915.
14. Chao H.T., Zoghbi H.Y., Rosenmund C. MeCP2 controls excitatory synaptic strength by regulating glutamatergic synapse number. Neuron 2007, 56:58-65.
15. Chen R.Z., Akbarian S., Tudor M., Jaenisch R. Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nat. Genet. 2001, 27:327-331.
16. Cohen S., Zhou Z., Greenberg M.E. Medicine. Activating a repressor. Science 2008, 320:1172-1173.
17. Duman R.S., Newton S.S. Epigenetic marking and neuronal plasticity. Biol. Psychiatry 2007, 62:1-3.
18. Eckhardt F., Lewin J., Cortese R., Rakyan V.K., Attwood J., Burger M., Burton J., Cox T.V., Davies R., Down T.A., Haefliger C., Horton R., Howe K., Jackson D.K., Kunde J., Koenig C., Liddle J., Niblett D., Otto T., Pettett R., Seemann S., Thompson C., West T., Rogers J., Olek A., Berlin K., Beck S. DNA methylation profiling of human chromosomes 6, 20 and 22. Nat. Genet. 2006, 38:1378-1385.
19. Egger G., Liang G., Aparicio A., Jones P.A. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004, 429:457-463.
20. Feinberg A.P. Phenotypic plasticity and the epigenetics of human disease. Nature 2007, 447:433-440.
21. Gardiner-Garden M., Frommer M. CpG islands in vertebrate genomes. J. Mol. Biol. 1987, 196:261-282.
22. Host L., Dietrich J.B., Carouge D., Aunis D., Zwiller J. Cocaine self-administration alters the expression of chromatin-remodelling proteins; modulation by histone deacetylase inhibition. J. Psychopharmacol. 2009, (Electronic publication ahead of print) doi:10.1177/0269881109348173.
23. Huang H.S., Matevossian A., Jiang Y., Akbarian S. Chromatin immunoprecipitation in postmortem brain. J. Neurosci. Methods 2006, 156:284-292.
24. Illingworth R., Kerr A., Desousa D., Jorgensen H., Ellis P., Stalker J., Jackson D., Clee C., Plumb R., Rogers J., Humphray S., Cox T., Langford C., Bird A. A novel CpG island set identifies tissue-specific methylation at developmental gene loci. PLoS Biol. 2008, 6:e22.
25. Jones P.L., Veenstra G.J., Wade P.A., Vermaak D., Kass S.U., Landsberger N., Strouboulis J., Wolffe A.P. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat. Genet. 1998, 19:187-191.
26. Jouvert P., Revel M.O., Lazaris A., Aunis D., Langley K., Zwiller J. Activation of the cGMP pathway in dopaminergic structures reduces cocaine-induced EGR-1 expression and locomotor activity. J. Neurosci. 2004, 24:10716-10725.
27. Kameshita I., Sekiguchi M., Hamasaki D., Sugiyama Y., Hatano N., Suetake I., Tajima S., Sueyoshi N. Cyclin-dependent kinase-like 5 binds and phosphorylates DNA methyltransferase 1. Biochem. Biophys. Res. Commun. 2008, 377:1162-1167.
28. Klose R.J., Bird A.P. Genomic DNA methylation: the mark and its mediators. Trends Biochem. Sci. 2006, 31:89-97.
29. Klose R.J., Sarraf S.A., Schmiedeberg L., McDermott S.M., Stancheva I., Bird A.P. DNA binding selectivity of MeCP2 due to a requirement for A/T sequences adjacent to methyl-CpG. Mol Cell. 2005, 19:667-678.
30. Li E. Chromatin modification and epigenetic reprogramming in mammalian development. Nat. Rev. Genet. 2002, 3:662-673.
31. Lin C., Franco B., Rosner M.R. CDKL5/Stk9 kinase inactivation is associated with neuronal developmental disorders. Hum. Mol. Genet. 2005, 14:3775-3786.
32. Lorincz M.C., Dickerson D.R., Schmitt M., Groudine M. Intragenic DNA methylation alters chromatin structure and elongation efficiency in mammalian cells. Nat. Struct. Mol. Biol. 2004, 11:1068-1075.
33. Ludwig M.G., Basset P., Anglard P. Multiple regulatory elements in the murine stromelysin-3 promoter. Evidence for direct control by CCAAT/enhancer-binding protein beta and thyroid and retinoid receptors. J. Biol. Chem. 2000, 275:39981-39990.
34. Marchi M., Guarda A., Bergo A., Landsberger N., Kilstrup-Nielsen C., Ratto G.M., Costa M. Spatio-temporal dynamics and localization of MeCP2 and pathological mutants in living cells. Epigenetics 2007, 2:187-197.
35. Mari F., Azimonti S., Bertani I., Bolognese F., Colombo E., Caselli R., Scala E., Longo I., Grosso S., Pescucci C., Ariani F., Hayek G., Balestri P., Bergo A., Badaracco G., Zappella M., Broccoli V., Renieri A., Kilstrup-Nielsen C., Landsberger N. CDKL5 belongs to the same molecular pathway of MeCP2 and it is responsible for the early-onset seizure variant of Rett syndrome. Hum. Mol. Genet. 2005, 14:1935-1946.
36. McGill B.E., Bundle S.F., Yaylaoglu M.B., Carson J.P., Thaller C., Zoghbi H.Y. Enhanced anxiety and stress-induced corticosterone release are associated with increased Crh expression in a mouse model of Rett syndrome. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:18267-18272.
37. McGowan P.O., Sasaki A., D'Alessio A.C., Dymov S., Labonte B., Szyf M., Turecki G., Meaney M.J. Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nat. Neurosci. 2009, 12:342-348.
38. Metivier R., Gallais R., Tiffoche C., Le Peron C., Jurkowska R.Z., Carmouche R.P., Ibberson D., Barath P., Demay F., Reid G., Benes V., Jeltsch A., Gannon F., Salbert G. Cyclical DNA methylation of a transcriptionally active promoter. Nature 2008, 452:45-50.
39. Miranda T.B., Jones P.A. DNA methylation: the nuts and bolts of repression. J. Cell. Physiol. 2007, 213:384-390.
40. Muller S.R., Sullivan P.D., Clegg D.O., Feinstein S.C. Efficient transfection and expression of heterologous genes in PC12 cells. DNA Cell Biol. 1990, 9:221-229.
41. Nan X., Campoy F.J., Bird A. MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell 1997, 88:471-481.
42. Nan X., Ng H.H., Johnson C.A., Laherty C.D., Turner B.M., Eisenman R.N., Bird A. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998, 393:386-389.
43. Newton S.S., Duman R.S. Chromatin remodeling: a novel mechanism of psychotropic drug action. Mol. Pharmacol. 2006, 70:440-443.
44. Numachi Y., Shen H., Yoshida S., Fujiyama K., Toda S., Matsuoka H., Sora I., Sato M. Methamphetamine alters expression of DNA methyltransferase 1 mRNA in rat brain. Neurosci. Lett. 2007, 414:213-217.
45. Ooi S.K., Bestor T.H. The colorful history of active DNA demethylation. Cell 2008, 133:1145-1148.
46. Peddada S., Yasui D.H., LaSalle J.M. Inhibitors of differentiation (ID1, ID2, ID3 and ID4) genes are neuronal targets of MeCP2 that are elevated in Rett syndrome. Hum. Mol. Genet. 2006, 15:2003-2014.
47. Pelka G.J., Watson C.M., Radziewic T., Hayward M., Lahooti H., Christodoulou J., Tam P.P. Mecp2 deficiency is associated with learning and cognitive deficits and altered gene activity in the hippocampal region of mice. Brain 2006, 129:887-898.
48. Razin A. CpG methylation, chromatin structure and gene silencing-a three-way connection. Embo J. 1998, 17:4905-4908.
49. Ricciardi S., Kilstrup-Nielsen C., Bienvenu T., Jacquette A., Landsberger N., Broccoli V. CDKL5 influences RNA splicing activity by its association to the nuclear speckle molecular machinery. Hum. Mol. Genet. 2009, 18:4590-4602.
50. Romieu P., Host L., Gobaille S., Sandner G., Aunis D., Zwiller J. Histone deacetylase inhibitors decrease cocaine but not sucrose self-administration in rats. J. Neurosci. 2008, 28:9342-9348.
51. Rusconi L., Salvatoni L., Giudici L., Bertani I., Kilstrup-Nielsen C., Broccoli V., Landsberger N. CDKL5 expression is modulated during neuronal development and its subcellular distribution is tightly regulated by the C-terminal tail. J. Biol. Chem. 2008, 283:30101-30111.
52. Russo S., Marchi M., Cogliati F., Bonati M.T., Pintaudi M., Veneselli E., Saletti V., Balestrini M., Ben-Zeev B., Larizza L. Novel mutations in the CDKL5 gene, predicted effects and associated phenotypes. Neurogenetics 2009, 10:241-250.
53. Scala E., Ariani F., Mari F., Caselli R., Pescucci C., Longo I., Meloni I., Giachino D., Bruttini M., Hayek G., Zappella M., Renieri A. CDKL5/STK9 is mutated in Rett syndrome variant with infantile spasms. J. Med. Genet. 2005, 42:103-107.
54. Song F., Mahmood S., Ghosh S., Liang P., Smiraglia D.J., Nagase H., Held W.A. Tissue specific differentially methylated regions (TDMR): changes in DNA methylation during development. Genomics 2009, 93:130-139.
55. Takai D., Jones P.A. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:3740-3745.
56. Tao J., Van Esch H., Hagedorn-Greiwe M., Hoffmann K., Moser B., Raynaud M., Sperner J., Fryns J.P., Schwinger E., Gecz J., Ropers H.H., Kalscheuer V.M. Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5/STK9) gene are associated with severe neurodevelopmental retardation. Am. J. Hum. Genet. 2004, 75:1149-1154.
57. Tao J., Hu K., Chang Q., Wu H., Sherman N.E., Martinowich K., Klose R.J., Schanen C., Jaenisch R., Wang W., Sun Y.E. Phosphorylation of MeCP2 at Serine 80 regulates its chromatin association and neurological function. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:4882-4887.
58. Tsankova N., Renthal W., Kumar A., Nestler E.J. Epigenetic regulation in psychiatric disorders. Nat. Rev. Neurosci. 2007, 8:355-367.
59. Tudor M., Akbarian S., Chen R.Z., Jaenisch R. Transcriptional profiling of a mouse model for Rett syndrome reveals subtle transcriptional changes in the brain. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:15536-15541.
60. Van Esch H., Bauters M., Ignatius J., Jansen M., Raynaud M., Hollanders K., Lugtenberg D., Bienvenu T., Jensen L.R., Gecz J., Moraine C., Marynen P., Fryns J.P., Froyen G. Duplication of the MECP2 region is a frequent cause of severe mental retardation and progressive neurological symptoms in males. Am. J. Hum. Genet. 2005, 77:442-453.
61. Weaving L.S., Christodoulou J., Williamson S.L., Friend K.L., McKenzie O.L., Archer H., Evans J., Clarke A., Pelka G.J., Tam P.P., Watson C., Lahooti H., Ellaway C.J., Bennetts B., Leonard H., Gecz J. Mutations of CDKL5 cause a severe neurodevelopmental disorder with infantile spasms and mental retardation. Am. J. Hum. Genet. 2004, 75:1079-1093.
62. Weber M., Davies J.J., Wittig D., Oakeley E.J., Haase M., Lam W.L., Schubeler D. Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat. Genet. 2005, 37:853-862.
63. Zhou Z., Hong E.J., Cohen S., Zhao W.N., Ho H.Y., Schmidt L., Chen W.G., Lin Y., Savner E., Griffith E.C., Hu L., Steen J.A., Weitz C.J., Greenberg M.E. Brain-specific phosphorylation of MeCP2 regulates activity-dependent Bdnf transcription, dendritic growth, and spine maturation. Neuron 2006, 52:255-269.